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Abstract 
 
Cancer screening is widely practiced and participation is promoted by various social, technical, and 
commercial drivers, but there are growing concerns about the emerging harms, risks, and costs of 
cancer screening. Deliberative democracy methods engage citizens in dialogue on substantial and 
complex problems: especially when evidence and values are important and people need time to 
understand and consider the relevant issues. Information derived from such deliberations can 
provide important guidance to cancer screening policies: citizens’ values are made explicit, revealing 
what really matters to people and why. Policy makers can see what informed, rather than 
uninformed, citizens would decide on the provision of services and information on cancer screening. 
Caveats can be elicited to guide changes to existing policies and practices. Policies that take account 
of citizens’ opinions through a deliberative democracy process can be considered more legitimate, 
justifiable, and feasible than those that don’t. 
 
 
In 2007 in New Zealand, 80 women aged 40 to 49 years were selected randomly from the electoral 
roll and invited, by letter, to participate in answering an important policy question: Should the New 
Zealand government offer free screening mammograms to women of their age? Of those original 80 
women, 46 could be contacted, 17 agreed to take part, and the first 12 to reply were invited to 
attend (1). The 11 women who were able to attend the first meeting believed, like many citizens in 
developed countries (2,3), that screening for cancer was a good thing to do. They all supported 
mammography for women of their age. The group was briefed on the topic on a Wednesday 
evening. That Friday they heard presentations from a range of cancer screening experts, with 
opportunities to ask questions, examine the evidence, and deliberate among themselves with 
support from an independent moderator. The next morning they conferred again, and then, with no 
advisors present, they reached a conclusion on the question posed. Their answer? At 10 :  1, they 
now voted against recommending government provision of mammographic screening for women 
aged 40 to 49 years. They also provided two lists: a list of reasons for their decision, and a list of 
provisos for their decision (1). 
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We cite the example above to illustrate the process of deliberative democracy, an approach that has 
been proposed and modelled around the world to elicit citizens’ values and priorities on challenging 
or controversial issues (4–9). In this commentary, we propose that application of deliberative 
democracy methods to inform policies about cancer screening is timely and offers great potential in 
terms of enhanced accountability. We will describe what deliberative democracy methods entail and 
their potential contribution to health policy, why such an approach is needed to inform cancer 
screening, and what types of policy questions might be considered. 
 
Deliberative Democracy Methods: What They Are and What They Offer 
 
Deliberative democracy methods are used to engage citizens in formal iterative dialogue on 
important and complex problems. There are many forms of deliberative methods available, including 
citizens juries, consensus conferences, deliberative polling, study circles, and citizens assemblies, as 
well as emerging options online (9,10). Such methods engage participants in an two-way process of 
information exchange between the sponsor (e.g., government or other agency) and the public, thus 
distinguishing them from other types of citizen engagement, such as public communication (where 
the sponsor informs public) or public consultation (where the public informs the sponsor) (10,11). 
The primary goal of deliberative democracy is to bring peoples’ opinions and values into a policy 
process while attempting to address concerns that public opinion may be ill-informed, poorly 
considered, or insufficiently responsive to alternative points of view (12–15). Hence most 
deliberative methods share the following essential core elements: they 1) provide balanced factual 
information; 2) seek to include people with diverse perspectives and potentially conflicting views; 3) 
create opportunities to reflect and discuss issues freely and to challenge and test competing claims; 
and 4) are potentially transformative for the participants. These elements are intended to ensure 
the views arrived at are informed, robust, and reliable (6,8,10,11,16). Policies that take account of 
citizens’ opinions through a deliberative democracy process can be considered more legitimate, 
justifiable, and feasible than those that don’t (17). 
 
Public deliberations can be affected by the questions posed, the choice of presenting experts, and 
the self-selection of participants. An early experiment with these methods has been subject to much 
controversy because it was framed in a process of health-care rationing (18). Clarity about the 
purpose and scope of deliberations, intended representation, and the recruitment of participants 
will enhance the validity and relevance of the output (19). Other process measures to support 
credible deliberations include random selection of participants, a steering committee to oversee 
selection of presenting experts, and an independent facilitator (20). A trial of public deliberation 
methods overseen by the Agency for Healthcare Research and Quality will provide important 
empirical data on the strengths and limitations of alternative approaches (21). Also important are 
broadening the reach and scale of public deliberations and finding the best way of integrating the 
outputs of deliberations into policy decisions (22). Research in these areas would offer important 
synergies with existing initiatives that seeks to enhance citizen engagement in health research, such 
as the Patient-Centred Outcomes Research Institute (23,24). 
 
Finally, to avoid public disillusionment, it is important to clarify whether a deliberation is integral to a 
policy development process or conducted for research or advocacy. For real policy impact, there 
must be genuine commitment from policy makers to incorporate the results into their decisions (5). 
Deliberative democracy does not replace the formal moral reasoning offered by ethicists (25). But by 
creating conditions in which members of the public can have informed discussions of collective 
problems [and reframe the problems if required (26)], deliberative processes can result in more just 
3 |  P a g e
 
and accountable recommendations on what ought to be done and contribute to more responsive 
policies (8,22,27). 
 
Why Deliberative Democracy Has Merit for Cancer Screening Policy 
 
Deliberative methods are particularly useful for questions in which values, ethics, and evidence are 
important and people need time to fully understand and consider all of the relevant issues (8,17). 
Deliberative methods can also identify areas of common ground on contentious issues and 
investigate balanced solutions to difficult problems (11,17). Deliberative democracy is thus most 
valuable for the following policy conditions (5,7,17): 
 
1. When the issue is of great public importance (e.g., affects many people or affects a smaller 
number of people profoundly, consumes considerable public funds, is about the public good 
or what “we” as a community should do); 
 
2. When the impact of a policy decision is morally significant (e.g., there are important conflicts 
between ethical considerations such as beneficence, respect for autonomy, reciprocity, or 
justice); 
 
3. When the policy decision requires an understanding of the evidence but cannot be resolved by 
technical or scientific evidence alone (e.g., there is disagreement among experts, decision 
depends strongly on the values people hold, and opinions are likely to be diverse); and 
 
4. When there is ongoing controversy and need for resolution (e.g., the status quo is contested, 
debates are divisive as advocates push in different directions, or there is scope to inform and 
enhance the legitimacy of a politically sensitive decision). 
 
The remainder of this paper outlines how these conditions apply to cancer screening and how 
deliberative democracy methods offer a way forward. 
 
The Public Importance of Cancer Screening 
 
The past three decades have led to wide-spread institutionalization of many types of cancer 
screening. Most of this is conducted in three contexts:  
 
1) dedicated programs organized at a population level (e.g., government programs screening 
for breast cancer, cervical cancer, and bowel cancer);  
2) opportunistic screening offered within health-care encounters [e.g., Prostate-Specific 
Antigen (PSA) testing for prostate cancer (28)]; and  
3) through tests purchased by individual consumers in a commercial market [e.g., full- or part-
body computed tomography scans for lung, colon, or other cancers (29)]. 
 
In most developed countries, recommended forms of screening for cancers such as breast cancer, 
cervical cancer, or bowel cancer have been actively promoted, with the public encouraged to 
participate through recruitment strategies such as television advertisements and targeted invitation 
letters or reminders. Participation rates are often identified as key performance indicators for 
centrally organized programs (30). There is often also poor understanding of the limitations and 
downsides of cancer screening, both among the general public and among clinicians (3,31–33). 
Technological developments and their promotion by those with interests in the new technologies 
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have further contributed to the rise in cancer screening (34–36). And privately and commercially 
available screening options continue to increase (37). Thus in a positive-feedback cycle, the 
promotion of screening has fed public expectations and public demand, and governments have in 
turn responded to the public discourse about cancer screening rights and entitlements (35). Notably, 
even cautious changes to screening guidelines can lead to vocal backlash from clinicians, public 
advocates, and politicians when the revisions involve scaling back established screening activity (38–
41). As a result, it can be difficult to revise cancer screening policy in line with the evolving evidence 
when this suggests a need to screen less. 
 
Concerns about the risks and harms of cancer screening are growing in the medical literature, 
particularly regarding PSA screening for prostate cancer (28) and, increasingly, mammography for 
breast cancer (42,43). There are also concerns that screening for all types of cancer is being 
practiced as an unquestioned component of routine health care (44). For example, doctors may 
recommend or initiate PSA testing without discussing the limitations or potential harms with their 
patients (45), and most pamphlets on mammography promote the benefits of screening but don’t 
address its limitations and harms (46–49). And although some screening, such as for cervical cancer, 
is widely accepted as beneficial, physicians may incorporate it into routine health examinations 
without patients understanding what has been done or the potential implications for them (50,51). 
Such concerns raise the challenge and importance of informed consent in cancer screening (52–54) 
and the need for decisions about participation to be appropriately supported (55,56) and highlight 
the benefits of shared decision making (57). It is also apparent that some people prefer to be 
advised and want clear expert guidance on what to do (58–60). 
 
The Moral Significance of Cancer Screening 
 
Cancer screening raises a number of ethical concerns about issues such as consent, respect for 
autonomy, non-maleficence, and justice. These concerns arise from the nature of screening (61) and 
appear heightened with screening for cancer. The ethically important characteristics of screening 
that make the public accountability of policy and practice imperative include: 
 
 the targeting of people who have no identified symptoms, thus potentially converting 
healthy individuals into patients (this problem is worse when there are substantial rates of 
overdiagnosis) (62); 
 
 the initiation of screening by the health sector and not by the individuals to be screened 
(i.e., a screening program, other health sector body, or health-care provider raises public 
awareness of the risk of cancer and promotes the apparent need to be screened); and 
 
 the delivery of screening to very large numbers of people, of whom some will benefit but 
some will be adversely affected. 
 
All screening is based on the rationale that early detection and early treatment of disease can 
benefit health and well-being, but it should only be offered when there is good evidence that the 
potential benefits outweigh the potential harms ( 63–65). Early evaluations found some benefits 
from cancer screening, but subsequent evidence also identified a number of harms. Harms can arise 
from overdiagnosis of indolent cancers (28,43,49,66–69) and the strong imperative to treat, as well 
as from false negatives, false positives, and invasive confirmatory tests (70–73). New screening 
technologies with increased sensitivity (e.g., magnetic resonance imaging for breast cancer 
screening) raise concerns about increasing overdiagnosis and overtreatment of cancers (42,74–77). 
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As the uncertain balance of benefits and harms becomes more apparent, greater attention is being 
given to supporting adequately informed choice and respecting individual autonomy rather than 
pursuing active recruitment to maximize the uptake of cancer screening (56,78,79). Yet even offers 
of screening have potential to harm individuals if those who decline are left with guilt about their 
choice or anxiety about whether they made the right decision (56,80,81). The public perception, 
created by the health sector, that cancer screening is good feeds, in turn, normative expectations of 
screening as the “right” thing to do. Many believe that even an 80-year-old who chooses not to be 
screened for cancer is irresponsible (32). To undo the notion that to participate in screening is a form 
of obligation (41,82) will require shifts in current perceptions about the benefits and harms of cancer 
screening and changes to cancer screening policy and practices. 
 
Cancer screening can also serve or undermine social justice (83). Those concerned about justice in 
screening often emphasize equity of access to screening services and have sought to increase 
recruitment among cultural minorities or groups of lower socioeconomic status. But equal access 
does not ensure social justice, and other considerations must be taken into account. For example, a 
favourable balance of the benefits and harms of screening in the particular target group is vital, as is 
the availability of sufficient, affordable, and high-quality treatment for those in whom cancer is 
detected. Further, how screening is offered is important, including whether communications support 
or undermine respect, personal security, and self-determination (51,77). Strong persuasion tactics 
may diminish individuals’ opportunities to be informed about the harms of screening, erode their 
ability to reason clearly about their screening choices, or undermine their sense of personal security 
if it generates new fears about developing cancer. Such effects occur at collective as well as 
individual levels, so that when particular populations are targeted, the undermining of social justice 
can be amplified. When the benefit/harm ratio is finely balanced, these problems are less likely to be 
countered by real improvement in health outcomes. 
 
Evidence Alone Is Not Sufficient to Guide Cancer Screening Policy and Practice 
 
Many developed countries employ systematic processes to guide evidence-based recommendations 
and policies on cancer screening, incorporating rigorous criteria for reviewing the technical evidence 
(84–86). But final judgments on the overall merits of policies on cancer screening are informed by 
the values of the decision makers, as the relative benefits and harms, the probabilities of these 
occurring, and the costs of screening must be subjectively weighed and valued (87). The interrelated 
policy and practice questions of primary public interest are: What types of cancer screening should 
be offered, to whom, and how should this be done? These evaluations have practical implications for 
which types of cancer screening should be centrally organized and publicly funded (88) and what 
community-level regulations, or even restrictions, should be imposed when evidence of a potential 
net harm becomes more apparent. It has also been suggested we need transparent conversations 
about the opportunity costs of cancer screening relative to other interventions, such as primary 
prevention of cancer (e.g., human papillomavirus vaccination, obesity prevention) and cancer 
treatment services (see Box 1) (40). 
 
The substantial harms associated with some forms of cancer screening may become so concerning 
as to sway the distribution of resources, but people vary in what harms and costs they consider 
worthwhile to save a life (1). 
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Box1: Important questions for cancer screening policy and practice that draw on evidence and values and 
could be informed by deliberative democracy methods  
 
1. For which cancers should screening be offered?  
2. To whom should this screening be offered (e.g., age groups)?  
3. How should this screening be offered?  
4. For which cancers should screening be centrally organized and publicly funded?  
5. What regulations, or even restrictions, should be imposed when the potential for a net harm becomes 
apparent? 
6. What proportion of resources for cancer should be allocated to screening relative to other 
interventions, such as primary prevention and cancer treatment services?  
 
Population-level decisions to support screening also create dilemmas for individuals. To make an 
informed choice, potential participants weigh uncertain personal benefit against uncertain harms, 
and questions such as “Will this test save my life?” and “Will this test harm me?” cannot be 
answered to guide their choice. Thus, although policy decisions require different types of 
considerations to those undertaken in clinical settings, both kinds of decisions have implications that 
require an explicit examination of ethics and values, as well as the scientific evidence.  
 
Some Forms of Cancer Screening are Hotly Contested and There Is a Need for Resolution 
 
Some of the main controversies in cancer screening have emerged when new evidence is presented 
to challenge the status quo, such as when a systematic review has major implications for an existing 
screening program [e.g., (68)]. The stakes become even greater when evidence-based guidelines are 
revised to recommend less frequent screening [e.g., (89,90)], or no screening [e.g., (66,91,92)] 
against the prevailing trends of clinical practice. As noted before, screening for prostate cancer has 
always been disputed. For example, in a 2002 “PSA Storm,” two experts opposed to PSA screening in 
the San Francisco Chronicle were bombarded with “accusations, abuse, and threats” (93). More 
recently the creator of the PSA test wrote that he “never dreamed that my discovery four decades 
ago would lead to such a profit-driven public health disaster” (94,95). Updated evidence (96,97) and 
a revised US Preventive Services Task Force recommendation against prostate cancer screening have 
added firmer ground to deliberations but have not resolved what the appropriate policy and practice 
response should be (91,98,99).  
 
Expert opinion is also divided on the implications of current evidence for continuing to offer 
mammography screening (69,100–105). Mammography was already a “highly emotional” 
controversy in 1977, with experts strongly divided on whether screening programs would “save 
many lives” or “produce potentially fatal illness” (106). More than 30 years later, the potential harms 
of the since well-established screening programs are again hotly contested (42,57). Such conflicts 
result in confusing public communication [e.g., (107)] and can erode public trust in clinical and public 
health expertise (108).  
 
A Way Forward to Guide Cancer Screening Policy and Practice: Combining Evidence and Citizens’ 
Values Through the Methods of Deliberative Democracy  
 
The New Zealand case study cited at the beginning of this commentary provides a striking example 
of the potential value of a focused deliberative process to facilitate informed public examination of a 
cancer screening policy. The process generated detailed information on what these informed 
women considered important and why for a mammography policy that might affect them. This 
7 |  P a g e
 
information included detailed provisos for their decision, such as that although they would not 
recommend commencing mammography for women aged 40 to 49 years, the existing policy of 
allowing access to free screening from age 45 should not be changed back to 50 (1). Another 
deliberative process on colorectal cancer screening, conducted in Ontario, Canada, identified 
important public concerns that had not been considered by the previously consulted scientific expert 
panel. This included the lack of public information about all screening options and the potential 
impact on the patient–provider relationship for those who don’t wish to be screened (12,17).  
Many stakeholders contribute to cancer screening policies, including clinician groups, laboratories 
and device manufacturers, patient advocacy groups, cancer charities and research groups, screening 
funders, and service providers, but there has been limited formal engagement of the public who are 
potential recipients of screening. The information derived from a deliberative democracy process 
can redress this by providing important guidance on cancer screening policies in the following ways:  
 
 Citizens’ values and priorities are made explicit, thereby revealing what really matters to 
people in cancer screening, and why;  
 Decision makers can see what informed, rather than uninformed, citizens would decide on 
the provision of services and information on cancer screening;  
 Caveats can be elicited to guide potential changes to existing policies and practices; 
 The information gained can be used to communicate about cancer screening policies, thus 
potentially increasing both the legitimacy and perceived legitimacy of the policy process; 
and  
 The information gained can also contribute toward supporting individuals making decisions 
about screening, enabling them to develop and clarify their own values and priorities by 
comparing them with the values and priorities of others.  
 
As indicated earlier, the process of deliberation on cancer screening must pay attention to issues of 
representation and recruitment (e.g., whether deliberations should recruit from the general 
population or only from the target group for a particular type of screening). It may be important to 
strike a balance between those who have not yet participated in a type of screening (e.g., PSA 
testing or mammography) and those who have already been screened—with and without adverse 
effects. Also important is policy-level commitment to the outputs of deliberations. There should be 
clear and demonstrable links between the public deliberation process and screening policy decisions, 
so everyone is clear on how the output of deliberations will be considered by relevant decision 
makers. And finally, longer-term commitments to a number of deliberations over time that address a 
range of different cancer screening policy decisions will offer a more complete picture of what 
citizens value in cancer screening and why than one-off deliberations around a single topic.  
 
In conclusion, cancer screening is an important public issue and government policies must somehow 
accommodate and reconcile disputed interpretations of the evidence. Although independent 
evidence-based expert advice on cancer screening is essential, government policies are invariably 
also influenced by the prevailing political climate, resource and other constraints, and the beliefs and 
priorities of those with political influence (38,39,109). For cancer screening policies to be sufficiently 
accountable, it is essential that policies also reflect the priorities and values of affected citizens. We 
propose that deliberative democracy methods could assist in resolving important questions about 
existing cancer screening practice and programs and improve future public accountability in this 
highly contested area.  
 
 
 
8 |  P a g e
 
Funding 
The Screening and Test Evaluation Program (STEP) is funded by a program grant (402764 and 
633033) from the Australian National Health and Medical Research Council (NHMRC).  
 
 
References 
1. Paul C, Nicholls R, Priest P, McGee R. Making policy decisions about population screening 
for breast cancer: The role of citizens’ deliberation. Health Policy.2008;85(3):314–320. 
2. Woloshin S, Schwartz LM. The benefits and harms of mammography screening: 
understanding the trade-offs. JAMA.2010;303(2):164–165. 
3. Hoffman RM, Lewis CL, Pignone MP, et al. Decision-making processes for breast, colorectal, 
and prostate cancer screening: the DECISIONS survey. Med Decis Making.2010;30:53s–64s. 
4. The Jefferson Center. Citizens Jury Process. http://www.jefferson-center.org/ . Accessed 
May 17, 2012. 
5. Gregory J, Hartz-Karp J, Watson R. Using deliberative techniques to engage the community 
in policy development. Aust New Zealand Health Policy.2008;5:16. doi:10.1186/1743-8462-
5-16 
6. Smith G, Wales C. The theory and practice of citizens’ juries. Policy & Politics1999;27(3): 
295–308. 
7. Agency for Healthcare Research and Quality. Using Deliberative Methods to Engage 
Patients, Consumers and the Public. http://effectivehealthcare.ahrq.gov/index.cfm/slide-
presentation-deliberative-methods/transcript-usingdeliberative-methods-webinar/. 
Accessed April 17, 2012. 
8. Blacksher E, Diebel A, Pierre-Gerlier F, Dorr Goold S, Abelson J. What is public 
deliberation?. Hastings Cent Rep.2012;42(2):14–16. 
9. Goodin RE, Dryzek JS. Deliberative impacts: the macro-political uptake of mini-publics. 
Politics & Society.2006;34(2):219–244. 
10. Lukensmeyer CJ, Hasselblad Torres L. Public Deliberation: A  Manager’s Guide to Citizen 
Engagement: IBM Center for the Business of Government; 2006. 
http://www.whitehouse.gov/files/documents/ostp/opengov_inbox/ibmpubdelib.pdf 
(accessed 14 January 2013). 
11. Sheedy A, MacKinnon MP, Pitre S, Watling J. Handbook on Citizen Engagement: Beyond 
Consultation. Canadian Policy Research Networks; 2008. 
http://www.cprn.org/documents/49583_EN.pdf(accessed 14 January 2013). 
12. Bombard Y, Abelson J, Simeonov D, Gauvin FP. Eliciting ethical and social values in health 
technology assessment: A participatory approach. Soc Sci Med.2011;73(1):135–144. 
13. National Institute for Health and Clinical Excellence. About NICE: Citizens Council.  
http://www.nice.org.uk/aboutnice/howwework/citizenscouncil/citizens_council.jsp. 
Accessed May 2, 2012. 
9 |  P a g e
 
14. Abelson J, Giacomini M, Lehoux P, Gauvin FP. Bringing “the public” into health technology 
assessment and coverage policy decisions: from principles to practice. Health 
Policy.2007;82(1):37–50. 
15. European Network for Health Technology Assessment. HTA Core Model for Screening 
Technologies.  
http://www.eunethta.eu/upload/WP4/Public%20consultation/HTA_Screening_model_2nd
%20public%20draft.pdf. Accessed March 29, 2012. 
16. Dorr Goold S, Neblo MA, Kim SYH, et al. What is good public deliberation? 2012. Hastings 
Cent. Rep.2012;42(2):24–26. 
17. Solomon S, Abelson J. Why and when should we use public deliberation? Hastings Cent 
Rep.2012;42(2):17–20. 
18. Bodenheimer T. The Oregon health plan—lessons for the nation. N Engl J Med. 
1997;337(9): 651–656. 
19. O’Doherty K, Gauvin FP, Grogan C, Friedman W. Implementing a public deliberative forum. 
Hastings Cent Rep.2012;42(1):20–23. 
20. Parkin L,Paul C. Public good, personal privacy: a citizens’ deliberation about using medical 
information for pharmaco epidemiological research. J Epidemiol Community Health. 
2011;65(2):150–156. 
21. Agency for Healthcare Research and Quality. AHRQ Community Forum. 
http://effectivehealthcare.ahrq.gov/index.cfm/who-is-involved-in-the-effectivehealth-
care-program1/ahrq-community-forum/ . Accessed October 31, 2012. 
22. Abelson J, Warren M, Forest P-G. The future of public deliberation on health issues. 
Hastings Cent Rep.2012;42(2):27–29. 
23. Selby JV, Beal AC, Frank L. The Patient-Centered Outcomes Research Institute (PCORI) 
national priorities for research and initial research agenda. JAMA.2012;307(15):1583–1584. 
24. Patient Centered Outcomes Research Institute. Patient-Centered Outcomes Research. 
http://www.pcori.org/what-we-do/pcor/ . Accessed October 29, 2012. 
25. Ashcroft R. Fair process and the redundancy of bioethics: a polemic. Public Health 
Ethics.2008;1(1):3. 
26. McIver S. Healthy Debate: Independent Evaluation of Citizens’ Juries in Health Settings. 
London: The Kings Fund; 1998. 
27. Gastil J, Black LW, Deess EP, Leighter J. From group member to democratic citizen: how 
deliberating with fellow jurors reshapes civic attitudes. Hum Commun Res.2008;34(1):137–
169. 
28. Chapman S, Barratt A, Stockler M. Let sleeping dogs lie? What men should know before 
getting tested for prostate cancer. Sydney: Sydney University Press; 2010.  
http://ses.library.usyd.edu.au/bitstream/2123/6835/3/Letsleeping-dogs-lie.pdf . Accessed 
March 28, 2012. 
10 |  P a g e
 
29. Scan Directory.com. Why Get a Scan? 
http://www.scandirectory.com/content/why_get_a_body_scan.asp . Accessed April 17, 
2012  
30. Jacobsen KK, von Euler-Chelpin M. Performance indicators for participation in organized 
mammography screening.  J Public Health.2012;34(2):272–278. 
31. Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer 
screening in Europe. J Natl Cancer Inst.2009;101(17):1216–1220. 
32. Schwartz LM,Woloshin S, Fowler FJ, Welch HG. Enthusiasm for cancer screening in the 
United States. JAMA.2004;291(1):71–78. 
33. Wegwarth O, Schwartz LM, Woloshin S, Gaissmaier W, Gigerenzer G. Do physicians 
understand cancer screening statistics? A  national survey of primary care physicians in the 
United States. Ann Intern Med.2012;156(5):340–349. 
34. Willis E. The prostatic imperative and the social relations of medical technology. Int J 
Technol Assess Health Care.1997;13(4):602–612. 
35. Faulkner A. Resisting the screening imperative: patienthood, populations and politics in 
prostate cancer detection technologies for the UK. Sociol Health Illn.2012;34(2):221–233. 
36. Newman TB, Kohn MA. Screening tests. Evidence-based diagnosis. New York: Cambridge 
University Press; 2009:116–137. 
37. Cole A. UK patients are given advice on private screening. BMJ.2010;341:c5394. doi: 
http://dx.doi.org/10.1136/bmj.c5394 . 
38. Tanne JH. New recommendations on mammography and cervical cancer screening disrupt 
US health reform debate. BMJ.2009;339:b5012. doi: http://dx.doi.org/10.1136/bmj.b5012  
39. Raffle A, Gray M. Screening: Evidence and Practice. Oxford: Oxford University Press; 2007. 
40. Fletcher SW. Breast cancer screening: a 35-year perspective. Epidemiol 
Rev.2011;33(1):165–175. 
41. Armstrong N, Eborall H. The sociology of medical screening: past, present and future. Sociol 
Health Illn. 2012;34(2):161–176. 
42. Gotzsche  PC. Mammography Screening: Truth, Lies and Controversy: London: Radcliffe 
Publishing; 2012. 
43. Kalager M, Adami H-O, Bretthauer M, Tamimi RM. Overdiagnosis of invasive breast cancer 
due to mammography screening: results from the Norwegian screening program. Ann 
Intern Med.2012;156(7):491–499. 
44. Schwartz LM, Woloshin S. Endless screenings don’t bring everlasting health. New York 
Times. April 16, 2012:D5. 
45. Cooper CP, Merritt TL, Ross LE, John LV, Jorgensen CM. To screen or not to screen, when 
clinical guidelines disagree: primary care physicians’ use of the PSA test. Prev Med. 
2004;38(2):182–191. 
11 |  P a g e
 
46. Gotzsche PC,Hartling OJ, Nielsen M, Brodersen J, Jorgensen KJ. Breast screening: the facts 
or maybe not. BMJ.2009;338:b86. doi: http://dx.doi.org/10.1136/bmj.b86 . 
47. Baum M, Thornton H, Gotzsche PC, et al. Breast cancer awareness month. Still awaiting 
screening facts. BMJ.2010;341:c6152. doi: http://dx.doi.org/10.1136/bmj.c6152 . 
48. Mayor S. Critics attack new NHS breast screening leaflet for failing to address harms. 
BMJ.2010;341:c7267. doi: http://dx.doi.org/10.1136/bmj.c7267 . 
49. Elmore JG, Fletcher SW. Overdiagnosis in breast cancer screening: time to tackle an 
underappreciated harm. Ann Intern Med.2012;157(7):536–537. 
50. Blake DR, Weber BM, Fletcher KE. Adolescent and young adult women’s misunderstanding 
of the term pap smear. Arch Pediatr Adolesc Med.2004;158(10):966–970. 
51. Breitkopf CR,Pearson HC, Breitkopf DM. Poor knowledge regarding the pap test among 
low-income women undergoing routine screening. Perspect Sex Reprod Health. 
2005;37(2):78–84. 
52. Irwig L, Glasziou P. Informed consent for screening by community sampling. Eff Clin 
Pract.2000;3(1):47–50. 
53. Irwig L, McCaffery K, Salkeld G, Bossuyt P. Screening and choice—informed choice for 
screening: implications for evaluation.  BMJ.2006;332(7550):1148–1150. 
54. Schwartz PH,Meslin EM. The ethics of information: absolute risk reduction and patient 
understanding of screening. J Gen Intern Med.2008;23(6):867–870. 
55. Jepson RG, Hewison J, Thompson A, Weller D. Patient perspectives on information and 
choice in cancer screening: a qualitative study in the UK. Soc Sci Med.2007;65(5):890–899. 
56. Entwistle VA, Carter SM, Trevena L, et al. Communicating about screening. 
MJ.2008;337(7673):3. 
57. Stefanek ME. Uninformed compliance or informed choice? A  needed shift in our approach 
to cancer screening. J Natl Cancer Inst.2011;103(24): 1821–1826. 
58. Krist AH, Woolf SH, Johnson RE, Kerns JW. Patient education on prostate cancer screening 
and involvement in decision making. Ann Fam Med.2007;5(2):112–119. 
59. Woolf SH, Krist A. The liability of giving patients a choice: shared decision making and 
prostate cancer. Am Fam Physician.2005;71(10):1871–1872. 
60. Levinson W, Kao A, Kuby A, Thisted RA. Not all patients want to participate in decision 
making—a national study of public preferences. J Gen Intern Med.2005;20(6):531–535. 
61. Juth N, Munthe C. The Ethics of Screening in Health Care and Medicine: Serving Society or 
Serving the Patient? International Library of Ethics, Law, and the New Medicine, Volume 
51. Berlin: Springer; 2012. 
62. Welch BM, Schwartz L, Woloshin S. Overdiagnosed: Making People Sick in the Pursuit of 
Health. Boston: Beacon Press; 2011. 
12 |  P a g e
 
63. Thorner RM, Remein QR. Principles and Procedures in the Evaluation of Screening for 
Disease. Public Health Monograph no.  67 (Public Health Service publication no.  846). 
Washington, DC: Government Printing Office; 1961. 
64. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Geneva: World 
Health Organization; 1968. 
65. Rose G, Barker DJP. Epidemiology for the uninitiated: screening. BMJ.1978;2:1417. doi: 
http://dx.doi.org/10.1136/bmj.2.6149.1417 . 
66. Moyer VA. Screening for prostate cancer: US Preventive Services Task Force 
recommendation statement. Ann Intern Med. 2012;157(2):120–134. 
67. Welch HG, Schwartz LM, Woloshin S. Ramifications of screening for breast cancer: 1 in 4 
cancers detected by mammography are pseudo-cancers. BMJ.2006;332(7543):727. 
68. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane 
Database Syst Rev.2009;4:CD001877. 
69. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast 
cancer screening: an independent review. Lancet.2012;380(9855):1778–1786. 
70. Marshall KG. Prevention. How much harm? How much benefit? 4. The ethics of informed 
consent for preventive screening programs. Can Med Assoc J.1996;155(4):377–383. 
71. Silvestre MAA, Dans LF, Dans AL. Trade-off between benefit and harm is crucial in health 
screening recommendations. Part II: evidence summaries. J Clin Epidemiol.2011;64(3):240–
249. 
72. Dans LF, Silvestre MA, Dans AL. Trade-off between benefit and harm is crucial in health 
screening recommendations. Part I: general principles. J Clin Epidemiol.2011;64(3):231–
239. 
73. Brewer NT, Salz T, Lillie SE. Systematic review: the long-term effects of false-positive 
mammograms. Ann Intern Med.2007;146(7):502–510. 
74. Kuhl CK, Schrading S, Bieling HB, et  al. MRI for diagnosis of pure ductal carcinoma in situ: a 
prospective observational study. Lancet.2007;370(9586):485–492. 
75. Thorat MA. Should we undertake an MRI breast screening trial? 
Lancet.2007;370(9603):1902. 
76. Thornton H. Should we undertake an MRI breast screening trial? The Lancet. 
2007;370(9603): 1903. 
77. Kuhl C,Bieling HB, Wardelmann E, Kuhn W, Schild HH. MRI breast screening? Authors’ 
reply. Lancet.2008;371(9622):1416. 
78. Braun V, Gavey N. “With the best of reasons”: cervical cancer prevention policy and the 
suppression of sexual risk factor information. Soc Sci Med.1999;48(10):1463–1474. 
79. Raffle AE. Information about screening—is it to achieve high uptake or to ensure informed 
choice? Health Expect.2001;4(2):92–98. 
13 |  P a g e
 
80. Evans I, Thornton H, Chalmers I, Glasziou P. Earlier is not necessarily better. In: Testing 
Treatments: Better Research for Better Healthcare. 2nd ed. London: Pinter & Martin Ltd; 
2011:31–49. 
81. Connolly T, Reb J. Regret in cancer-related decisions. Health Psychol.2005;24(4):S29–S34. 
82. Howson A. Cervical screening, compliance and moral obligation. Sociol Health 
Illn.1999;21(4):401–425. 
83. Powers M, Faden R. Social Justice: The Moral Foundations of Public Health and Health 
Policy. Oxford: Oxford University Press; 2006. 
84. National Health Committee. Screening to Improve Health in New Zealand: Criteria to 
Assess Screening Programmes. http://www.nhc.govt.nz. Accessed January 18, 2011. 
85. UK National Screening Committee. Programme Appraisal Criteria: Criteria for Appraising 
the Viability, Effectiveness and Appropriateness of a Screening Programme. 
http://www.screening.nhs.uk/criteria. Accessed January 18, 2011. 
86. US Preventive Services Task Force. US Preventive Services Task Force Procedure Manual. 
AHRQ Publication No. 08-05118-EF.  
http://www.uspreventiveservicestaskforce.org/uspstf08/methods/procmanual.htm . 
Accessed January 18, 2011. 
87. Harris R. Overview of screening: where we are and where we may be headed. Epidemiol 
Rev.2011;33(1):1–6. 
88. Currow D, Armstrong B. PSA Needs Order. 
http://www.mjainsight.com.au/view?post=david-currow-bruce-armstrong-psa-needs-
order&post_id=6489&cat=comment . Accessed May 25, 2012. 
89. US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task 
Force recommendation statement. Ann Intern Med.2009;151(10):716. 
90. US Preventive Services Task Force. Screening for Cervical Cancer, US Preventive Services 
Task Force Recommendation Statement. 
http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancerrs.htm#clin
ical . Accessed April 4, 2012. 
91. Brett AS, Ablin RJ. Prostate-cancer screening—what the US Preventive Services Task Force 
left out. N Engl J Med.2011;365:1949–1951 doi: 10.1056/NEJMp1112191. 
92. Catalona WJ, D’Amico AV, Fitzgibbons WF, et al. What the US Preventive Services Task 
Force missed in its prostate cancer screening recommendation. Ann Intern 
Med.2012;157(2):137–138. 
93. Yamey G, Wilkes M. The PSA storm: questioning cancer screening can be a risky business in 
America. BMJ.2002;324(7334):431. 
94. Ablin RJ. The great prostate mistake. New York Times. March 10, 2010:A27. 
95. Ablin RJ, Haythorn MR. Screening for prostate cancer: controversy? What controversy? 
Curr Oncol.2009;16(3):1–2. 
14 |  P a g e
 
96. Chou R,Croswell JM, Dana T, et  al. Screening for prostate cancer: a review of the evidence 
for the US Preventive Services Task Force. Ann Intern Med.2011;155(11):762–771.  
97. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 Years of follow-
up. N Engl J Med.2012;366(11):981–990. 
98. Schröder FH. Stratifying risk—the US Preventive Services Task Force and prostate-cancer 
screening. N Engl J Med.2011;365:1953–1955. 
99. McNaughton-Collins MF, Barry MJ. One man at a time—resolving the PSA controversy. N 
Engl J Med.2011;365:1951–1953 doi: 10.1056/NEJMp11112140 . 
100. McPherson K. Screening for breast cancer: balancing the debate. BMJ.2010;340:c3106. doi: 
http://dx.doi.org/10.1136/bmj.c3106 . 
101. Javitt MC, Hendrick RE. Revealing Oz behind the curtain: USPSTF screening mammography 
guidelines and the hot air balloon.  Am J Roentgenol.2010;194(2):289–290. 
102. Baum M. Breast screening should be scrapped. Evidence points to the fact that cancer 
mortality rates are dropping due to improved treatment, not mammograms. The Guardian. 
August 2, 2011. http://www.guardian.co.uk/commentisfree/2011/aug/02/breast-cancer-
screening . Accessed January 8, 2013. 
103. Bock K, Borisch B, Cawson J, et al. Effect of population based screening on breast cancer 
mortality. Lancet.2011;378(9805):1775–1776 
104. Roder DM, Olver IN. Opposing views: do the benefits of screening mammography outweigh 
the harms: yes. Med J Aust.2012;196(1):16. 
105. Bell RJ, Burton RC. Opposing views: do the benefits of screening mammography outweigh 
the harms: no. Med J Aust.2012;169(1):17. 
106. Thier SO. Breast cancer screening: a view from outside the controversy. N Engl J 
Med.1977;275(19):1063–1065. 
107. Kolata G. Get a mammogram. No don’t. Repeat. New York Times. November 21, 2009:WK4. 
108. Slovic P. Trust, emotion, sex, politics, and science: surveying the risk assessment battlefield. 
Risk Anal.1999;19(4):689–701. 
109. Flitcroft K, Gillespie J, Salkeld G, Carter S, Trevena L. Getting evidence into policy: the need 
for deliberative strategies? Soc Sci Med.2011;72(7):1039–1046. 
 
